Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.

Autor: Breinholt MF; Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark., Schejbel L; Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark., Gang AO; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Nielsen TH; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Danish Medicines Agency, Copenhagen, Denmark., Pedersen LM; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Høgdall E; Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Nørgaard P; Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark.; Department of Pathology, Hvidovre Hospital, Hvidovre, Denmark.

Publikováno v: European journal of haematology [Eur J Haematol] 2023 Oct; Vol. 111 (4), pp. 583-591. Date of Electronic Publication: 2023 Jul 14.

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation.

Autor: Schejbel L; Department of Pathology Copenhagen University Hospital Herlev Denmark., Breinholt MF; Department of Pathology Copenhagen University Hospital Rigshospitalet Denmark., Gang AO; Department of Haematology Copenhagen University Hospital Rigshospitalet Denmark., Nielsen TH; Department of Haematology Copenhagen University Hospital Rigshospitalet Denmark., Pedersen LM; Department of Haematology Zealand University Hospital Roskilde Denmark., Høgdall E; Department of Pathology Copenhagen University Hospital Herlev Denmark., Nørgaard P; Department of Pathology Copenhagen University Hospital Herlev Denmark.

Publikováno v: EJHaem [EJHaem] 2022 Jun 24; Vol. 3 (3), pp. 936-939. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022).

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

Autor: Szabo AG; Department of Hematology, Vejle Hospital, Vejle, Denmark.; Department of Hematology Rigshospitalet, Copenhagen University, Copenhagen, Denmark., Thorsen J; COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark., Iversen KF; Department of Hematology, Vejle Hospital, Vejle, Denmark., Levring MB; Department of Hematology, Odense University Hospital, Odense, Denmark., Preiss B; Department of Pathology, Odense University Hospital, Odense, Denmark., Helleberg C; Department of Pathology, Herlev University Hospital, Herlev, Denmark., Breinholt MF; Department of Pathology, Herlev University Hospital, Herlev, Denmark., Hermansen E; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Gjerdrum LMR; Department of Pathology, Zealand University Hospital, Roskilde, Denmark., Bønløkke ST; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Nielsen K; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Kjeldsen E; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Teodorescu EM; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark., Dokhi M; Department of Hematology Rigshospitalet, Copenhagen University, Copenhagen, Denmark., Kurt E; Department of Hematology, Regionshospitalet Holstebro, Holstebro, Denmark., Strandholdt CN; Department of Hematology, Hospital of South West Jutland, Esbjerg, Denmark., Andersen MK; Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark., Vangsted AJ; Department of Hematology Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

Publikováno v: American journal of hematology [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E117-E120. Date of Electronic Publication: 2021 Dec 29.

The real-world outcomes of multiple myeloma patients treated with daratumumab.

Autor: Szabo AG; Department of Hematology, Vejle Hospital, Vejle, Denmark., Klausen TW; Department of Hematology, Herlev University Hospital, Herlev, Denmark., Levring MB; Department of Hematology, Odense University Hospital, Odense, Denmark., Preiss B; Department of Pathology, Odense University Hospital, Odense, Denmark., Helleberg C; Department of Hematology, Herlev University Hospital, Herlev, Denmark., Breinholt MF; Department of Pathology, Herlev University Hospital, Herlev, Denmark., Hermansen E; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Gjerdrum LMR; Department of Pathology, Zealand University Hospital, Roskilde, Denmark., Bønløkke ST; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Nielsen K; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Kjeldsen E; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Iversen KF; Department of Hematology, Vejle Hospital, Vejle, Denmark., Teodorescu EM; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark., Dokhi M; Department of Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark., Kurt E; Department of Hematology, Regionshospitalet Holstebro, Holstebro, Denmark., Strandholdt C; Department of Hematology, Esbjerg Hospital, Esbjerg, Denmark., Andersen MK; Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark., Vangsted AJ; Department of Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

Publikováno v: PloS one [PLoS One] 2021 Oct 13; Vol. 16 (10), pp. e0258487. Date of Electronic Publication: 2021 Oct 13 (Print Publication: 2021).

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

Autor: Klausen U; Dept. Of Hematology, Herlev Hospital, Herlev, Denmark.; Dept. Of Hematology, Rigshospitalet, Copenhagen, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Grønne Dahlager Jørgensen N; Dept. Of Hematology, Herlev Hospital, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark., Grauslund JH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Munir Ahmad S; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark., Gang AO; Dept. Of Hematology, Rigshospitalet, Copenhagen, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark., Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark., Breinholt MF; Dept. Of Pathology, Herlev Hospital, Herlev, Denmark., Novotny GW; Dept. Of Hematology, Herlev Hospital, Herlev, Denmark.; Dept. Of Pathology, Herlev Hospital, Herlev, Denmark., Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Orebo Holmström M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Pedersen LB; Dept. Of Hematology, Rigshospitalet, Copenhagen, Denmark., Poulsen CB; Dept. Of Hematology, Zealand University Hospital, Roskilde, Rosklide, Denmark., Hansen PB; Dept. Of Hematology, Zealand University Hospital, Roskilde, Rosklide, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Niemann CU; Dept. Of Hematology, Rigshospitalet, Copenhagen, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark., Pedersen LM; Dept. Of Hematology, Herlev Hospital, Herlev, Denmark.; Dept. Of Hematology, Rigshospitalet, Copenhagen, Denmark.; Dept. Of Hematology, Zealand University Hospital, Roskilde, Rosklide, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology Herlev Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen K, Denmark.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Sep 25; Vol. 10 (1), pp. 1975889. Date of Electronic Publication: 2021 Sep 25 (Print Publication: 2021).